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Currently, cryopreservation of oocytes, embryos and ovarian tissue is considered the basis of fertility preservation
programs for women with cancer and other diseases who are rendered sterile by gonadotoxic drugs or radiation.
Numerous studies have confirmed that autograft of frozen-thawed ovarian tissue can restore ovarian function and
fertility. A total of twenty-two live births have been reported but we still have to consider this technique as
experimental. The main problem is that the implant undergoes ischemia until neoangiogenesis is restored, resulting
in significant follicular loss.
At the moment, there are numerous publications in different medical fields that publish successful experiences with
plasma rich in platelets (PRP) in different clinical situations promoting angiogenesis. Thus, we considered the
possibility of using it in the field of ovarian autologous transplantation in order to improve the vascularization of
the implant and its quality. For this, both thawed ovarian tissue as practiced pockets on the rear side of the broad
ligament which have been placed, have been impregnated with PRP. We can say that the implant treated in this
way has had a rapid and successful response.
We report a special interesting case because this is the first time that this technique is performed successfully in a
woman without ovaries combined with growth factors to promote neoangiogenesis. Obviously, the results of the
hormonal response come exclusively from the implanted tissue in these special conditions.
Keywords: Platelet rich plasma, PRP, Antimüllerian hormone, AMH, Cryopreservation, Fertility preservation, Ovarian
tissue transplantationBackground
Currently, cryopreservation of oocytes, embryos and
ovarian tissue is considered the basis of fertility preser-
vation programs for women with cancer and other dis-
eases who are rendered sterile by gonadotoxic drugs or
radiation.
Numerous studies have confirmed that autograft of
frozen-thawed ovarian tissue can restore ovarian function
and fertility. A total of twenty-two live births in twelve
women have been reported [1-3], but this technique is still
considered experimental. The main problem is that the im-
plant undergoes ischemia until neoangiogenesis is restored,* Correspondence: callejo@hsjdbcn.org
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reproduction in any medium, provided the orresulting in significant follicular loss as noted in some ori-
ginal articles [4-6].
We report a special interesting case because this is the
first time that this technique is performed successfully in
a woman without ovaries combined with growth factors
to promote neoangiogenesis. Obviously, the hormonal
response comes exclusively from the implanted tissue
under these special conditions.Case presentation
In 2001, when the patient was 20 years old, she underwent
an urgent left oophorectomy due to a twisted necrosed
dermoid cyst of 15×10 cm. After two months, in the post-
surgical control, the ultrasound examination showed an-
other cyst of 3x2cm in the right ovary that again suggested
a dermoid cyst. A new surgery was proposed to the patientLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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25% of healthy ovarian tissue was left and it was emplaced
opposite to the vascular hilum and connected to it by just a
fibrous band with poor vascularization. Therefore, we pro-
ceeded to resect and cryopreserve the remained tissue
according to the fertility preservation protocol in oncologi-
cal patient of our hospital. The patient was informed of this
eventuality. The anathomo-pathologycal analysis confirmed
the clinical diagnosis of dermoid cyst in both tumors.
Clinical and biochemical premature ovarian insufficiency
(POI) was immediately observed; therefore, hormonal
replacement treatment (HRT) was started.
In 2011, when she was 30 years old, the patient wished to
become pregnant. HRT was stopped and the cryopreserved
ovarian tissue was reimplanted using growth factors to
boost neoangiogenesis. Four-and-a half months later, the
ovarian function was restored and the first spontaneous
menstruation ensued. Then, on the third day of menstrual
bleeding, ovarian stimulation for in vitro fertilization/
intracytoplasmatic sperm injection (IVF/ICSI) was started.
In each implant one follicle 6 mm developed. Peripheral
hormones showed the following levels: follicular stimulat-
ing hormone (FSH) 7,9 mIU/ml; and estradiol 58 pg/ml.
We used 300 units of recombinant FSH daily and on
the third day we added 150 units of recombinant
luteinizing hormone (LH), also daily (Gonal-F and Luveris,
Merk Serono). On day 6 of the stimulation, a daily admi-
nistration of 0.25 mg of a gonadotropin releasing hormone
(GnRH) antagonist (Cetrotide, Merck Serono) was ini-
tiated. On the ninth day of stimulation egg retrieval was
performed. Estradiol levels were 316 pg/ml. The ovulationFigure 1 The surgical procedure is extremely easy. The thawed ovarian
transferred using laparoscopic surgery to the pockets located in the posterwas triggered with human chorionic gonadotropin (HCG)
250 mcg (Ovitrelle, Merck Serono) followed by vaginal
administration of 200 mg micronized progesterone 3
times a day (Utrogestan, Laboratorios SEID S.A.) and
estradiol hemihydrate 0.78 mg transdermal every three
days (Estradot, Novartis Farmaceutica). The endomet-
rial thickening was 10 mm, and 3 follicles were retrieved
(two 14 mm on the right side and one 11 mm on the left
side). Two oocytes were obtained, one metaphase II (MII)
and the other metaphase I (MI) that developed to MII after
7 hours of culture). Both were inseminated by ICSI. On the
day +2 we transferred a 4 regular mononucleated cells em-
bryo and the other with 15% of fragmentation. Serum test-
ing for HCG was positive 13 days after the embryo transfer.
Repeated ultrasonography during the pregnancy showed
normal fetal growth and development. At 38 weeks and 6
days of gestation, a healthy boy weighing 3.500 Kg, Apgar
9–10, was delivered by caesarean section on July 31, 2012.
Freezing and thawing of ovarian tissue
Ovarian tissue was frozen in pieces of 2–3 mm3 using
dimethylsulphoxide (DMSO) and thawed according to
the protocol described elsewhere by our group [7].
Platelet rich plasma (PRP)
Platelet rich plasma was prepared starting with 60 mL of
patient´s blood drawn into tubes containing 3.2% of
citratated dextrose. Blood was centrifuged at 280 g for
15 minutes at room temperature, plasmatic fraction was
isolated and a second centrifugation was performed at
680 g during 20 minutes. The platelet pellet was dilutedtissue (A) is impregnated in a gel preparation of PRP (B) and it is
ior surface of the broad ligaments (C).
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was coated with PRP before implantation.
Multiple preparations of PRP for clinical use have been
described. Differences in volume, concentration of plate-
lets, white blood cells and even in the final presentation
(liquid or gel) define the observed variability of those
products. We performed a double-spin centrifugation
protocol to obtain the highest recovery of platelets to
promote a rapid neovascularization of the graft [8,9] but
with the minimal concentration of blood cells to avoid
undesirable catabolic and inflammatory related events
that could potentially affect the ovarian tissue [10,11].
Surgery
For the reimplantation we used all the frozen-thawed
small cubes of ovarian tissue (1–2 mm3). We created aFigure 2 Peripheral hormones levels of FSH, estradiol, Progesterone,
first positive HCG determination.peritoneal pocket in both posterior surfaces of the broad
ligament by laparoscopic surgery, where we placed the
cubes. Previously, we used a gel preparation of PRP to
impregnate the cubes and, after they have been located
in the peritoneal pockets performed, it proceeds to fill
these with the platelet gel using the 5 mL supplied
(Figure 1).
Hormone laboratory
Serum FSH, LH and HCG were measured by a chemilu-
miniscent microparticle immunoassay in an ARCHITECT
analyzer (Abbott Laboratories, Abbott Park, IL). Proges-
terone was measured by a Chemiluminescent enzyme
immunoassay in a IMMULITE2000 analyzer, SIEMENS
Healthcare Diagnostics. Anti-Mullerian Hormone (AMH)HCG, AMH and Inhibin B, from the first menstruation until the
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ELISA (BECHMAN COULTER, USA). Serum inhibin B
concentrations were measured using a highly sensitive
two-site enzymelinked immunosorbent assay ELISA;
(Diagnostic Systems Laboratories, Inc).Ethical considerations
The protocol was approved by the local Ethical Commit-
tee and the administrative authorization Ref. H08000875
Departament de Salut (Generalitat de Catalunya). The
patient and her partner received written information
about all the process and signed the informed consent.Results
Figure 2 shows the peripheral hormones levels of FSH,
estradiol, Progesterone, HCG, AMH and Inhibin B, from
the first menstruation until the first positive HCG deter-
mination. Figure 3 shows the hormonal changes during
pregnancy and immediate postpartum.Figure 3 Peripheral hormones levels of FSH, estradiol, Progesterone, HCDiscussion
Certainly, the main problem of autograft of frozen-
thawed ovarian tissue is the loss of more than 50% of
follicles caused by the ischemia that the autograft suffers
until neoangiogenesis is restored [4-6]. Today, investiga-
tors are working to improve this problem.
PRP is a blood product where a high level of platelets
is concentrated (about 1.000.000 of platelets/μL in 5 ml
of plasma) but with growth factors concentration 3 to 5
times greater than plasma. Growth factors are stored in
α granules, and include platelet derivated growth factor
(PDGFs), Transforming growth factor-beta (TGF-β), ves-
sel endothelial growth factor (VEGF), epidermal growth
factor (EGF), fibroblast growth factor (FGF) e insuline-
like growth factor (IGF) and some others [12,13]. These
cytokines play an important role in cellular proliferation,
chemotaxis and differentiation of mesenchymal and other
cells and promote angiogenesis [13].
There are already numerous publications in different
medical fields reporting successful experiences with PRP
that improve neoangiogenesis in different clinical situationsG, AMH and Inhibin B, during pregnancy and immediate pospartum.
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the field of ovarian autologous transplantation in order to
improve the vascularization of the implant and its quality.
The result has been successful in obtaining a healthy
baby in the first cycle of stimulation, but it has been
seen before [17,18] without the use of PRP. But with a
single case, one cannot draw any conclusions. More
studies are required to determine whether the use of
PRP represents a contribution.
We would like to highlight the results of the levels of
AMH: throughout the process, peripheral levels of this
hormone were undetectable (<0.1 ng / ml). These results
are consistent with the series of Janse et al. [19] and
Grave et al. [20]. Very low or undetectable levels of
AMH at the time of conception indicate a poor and
irregular pool of them which have already started their
development from primordial follicles.
We would like to make some observations on the in-
dication of egg retrieval when follicle sizes are about 14–
15 millimeters. Usually, these can be considered imma-
ture follicles, moreover if we obtain levels of estradiol
that correspond to a mature follicle in transplanted pa-
tients with this follicular size (14–15 mm), we should
consider that indirect clinical criteria of follicular matur-
ity in the autograft (follicular size and rate of estradiol),
do not necessarily have to be the same as in the normal
inserted ovary. When we perform ultrasound measure-
ments of the follicles we are measuring the antral diam-
eter without considering the possibility of a granulosa
layer hyperplasia that provides estradiol characteristic
levels of a mature follicle. In the experimental model,
when the reimplanted ovarian tissue is functioning, our
group shows this possibility [21,22].
At this point we would like to draw attention on the
recommendations of Oktay et al. in 2004 [23] who pro-
posed follicular maturity at a size of 10–11 mm in this
type of tissue. Demesteere et al. [24] who reported a spon-
taneous pregnancy after orthotopic graft in 2006, explains
that the follicles which developed in the subcutaneous
implant never reached the sufficient size to be retrieved
(maximum 13 mm). A year later, the same author [25], in
the second reimplantation to the same patient, which for-
tunately concluded with the announcement of the third
live birth from cryopreserved ovarian tissue, announced
that the two retrieved follicles of the implanted ovarian
measured 15 mm at the time of ovulation. Fourteen days
later chorionic gonadotropin levels were detected.
Nevertheless, many authors have retrieved follicles
above 17 mm obtaining good quality MII oocytes [1]
and these arguments must consider only speculation.
Conclusion
We report the second pregnancy occurred after ovarian
tissue cryopreservation for benign ovarian pathologyafter bilateral oophorectomy. Growth factors are used in
combination with frozen-thawed ovarian tissue to boost
neoangiogenesis. The result of this case was successful.
However, more studies are required to determine whether
the use of PRP represents a contribution.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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